Editing GSK plc (section)

===Philanthropy and social responsibility===
Since 2010, GlaxoSmithKline has several times ranked first among pharmaceutical companies on the Global Access to Medicines Index, which is funded by the [[Bill and Melinda Gates Foundation]].<ref name="www.accesstomedicineindex.org">{{cite web |url=http://www.accesstomedicineindex.org/sites/www.accesstomedicineindex.org/files/longitudinal_analysis_2010-2012_access_to_medicine_index.pdf |title=Access to medicine |url-status=dead |archive-url=https://web.archive.org/web/20140207165041/http://www.accesstomedicineindex.org/sites/www.accesstomedicineindex.org/files/longitudinal_analysis_2010-2012_access_to_medicine_index.pdf |archive-date=7 February 2014}}</ref> In 2014, the [[Human Rights Campaign]], an [[LGBT]]-rights advocacy group gave GSK a score of 100 per cent in its [[Corporate Equality Index]].<ref>Human Rights Campaign. [http://www.hrc.org/apps/buyersguide/profile.php?orgid=1563 Profile: Buyers Guide entry for GlaxoSmithKline] {{Webarchive |url=https://web.archive.org/web/20160513062232/http://www.hrc.org/apps/buyersguide/profile.php?orgid=1563 |date=13 May 2016 }}. Accessed 16 May 2014</ref>

GSK has been active, with the [[World Health Organization]] (WHO), in the Global Alliance to Eliminate Lymphatic Filariasis (GAELF). Around 120{{nbsp}}million people globally are believed to be infected with [[Filariasis|lymphatic filariasis]].<ref>{{cite web |url=http://www.ifpma.org/index.php?id=588 |archive-url=https://web.archive.org/web/20081227072400/http://www.ifpma.org/index.php?id=588 |archive-date=27 December 2008 |title=Global alliance to eliminate Lymphatic Filariasis |publisher=Ifpma.org}}</ref> In 2012, the company endorsed the [[London Declaration on Neglected Tropical Diseases]]; it agreed to donate 400{{nbsp}}million [[albendazole]] tablets to the WHO each year to fight [[soil-transmitted helminthiasis]] and to provide 600{{nbsp}}million albendazole tablets every year for lymphatic filariasis until the disease is eradicated.<ref name="bill">{{cite web |title=Private and Public Partners Unite to Combat 10 Neglected Tropical Diseases by 2020 |date=30 January 2012 |url=http://www.gatesfoundation.org/media-center/press-releases/2012/01/private-and-public-partners-unite-to-combat-10-neglected-tropical-diseases-by-2020 |publisher=Bill & Melinda Gates Foundation |access-date=30 May 2013 |archive-url=https://web.archive.org/web/20130314153950/http://www.gatesfoundation.org/media-center/press-releases/2012/01/private-and-public-partners-unite-to-combat-10-neglected-tropical-diseases-by-2020 |archive-date=14 March 2013 |url-status=dead }}{{pb}}
{{cite web |title=Research-based pharma pledges on neglected tropical diseases |date=31 January 2012 |url=http://www.thepharmaletter.com/file/110665/research-based-pharma-pledges-on-neglected-tropical-diseases.html |work=The Pharma Letter |access-date=30 May 2013 |archive-date=19 July 2012 |archive-url=https://web.archive.org/web/20120719035149/http://www.thepharmaletter.com/file/110665/research-based-pharma-pledges-on-neglected-tropical-diseases.html |url-status=live }}</ref> {{As of|2014}}, over 5{{nbsp}}billion treatments had been delivered, and 18 of 73 countries in which the disease is considered endemic had progressed to the surveillance stage.<ref>{{cite web |date=18 September 2015 |title=Global programme to eliminate lymphatic filariasis: progress report, 2014 |url=https://www.who.int/wer/2015/wer9038.pdf |url-status=dead |archive-url=https://web.archive.org/web/20151017042413/https://www.who.int/wer/2015/wer9038.pdf |archive-date=17 October 2015 |publisher=World Health Organization |page=490}}</ref>

In 2009, the company said it would cut drug prices by 25 per cent in 50 of the poorest nations, release intellectual property rights for substances and processes relevant to neglected disease into a [[patent pool]] to encourage new drug development, and invest 20 per cent of profits from the least-developed countries in medical infrastructure for those countries.<ref>{{Cite news |last=Boseley |first=Sarah |date=13 February 2009 |title=Drug giant GlaxoSmithKline pledges cheap medicine for world's poor |language=en-GB |work=The Guardian |url=https://www.theguardian.com/business/2009/feb/13/glaxo-smith-kline-cheap-medicine |url-status=live |access-date=11 September 2023 |archive-url=https://web.archive.org/web/20130905231853/http://www.theguardian.com/global-development |archive-date=5 September 2013 |issn=0261-3077}}</ref><ref>UNITAID 16 February 2009. [http://www.unitaid.eu/en/resources/press-centre/news/158-unitaid-statement-on-gsk-patent-pool-for-neglected-diseases UNITAID Statement on GSK Patent Pool For Neglected Diseases] {{Webarchive |url=https://web.archive.org/web/20140527215419/http://www.unitaid.eu/en/resources/press-centre/news/158-unitaid-statement-on-gsk-patent-pool-for-neglected-diseases |date=27 May 2014 }}</ref> [[Médecins Sans Frontières]] welcomed the decision, but criticized GSK for failing to include HIV patents in its patent pool and for not including middle-income countries in the initiative.<ref>{{Cite web |date=24 February 2009 |title=The Guardian: Letter in response to GSK's patent pool proposal |url=https://msfaccess.org/guardian-letter-response-gsks-patent-pool-proposal |archive-url=https://web.archive.org/web/20190620145600/https://msfaccess.org/guardian-letter-response-gsks-patent-pool-proposal |archive-date=20 June 2019 |access-date=11 September 2023 |website=Médecins Sans Frontières Access Campaign |language=en}}</ref>

In 2013, GSK licensed its HIV portfolio to the Medicines Patent Pool for use in children, and agreed to negotiate a license for [[dolutegravir]], an [[integrase inhibitor]] then in clinical development.<ref>{{Cite news |date=27 February 2013 |title=GlaxoSmithKline unit joins patent pool for AIDS drugs |newspaper=Reuters |url=https://www.reuters.com/article/us-aids-drugs-patents-idUSBRE91Q0P520130227 |url-status=live |archive-url=https://web.archive.org/web/20230404232539/https://www.reuters.com/article/us-aids-drugs-patents-idUSBRE91Q0P520130227 |archive-date=4 April 2023}}</ref> In 2014, this license was extended to include dolutegravir and adults with HIV. The licenses include countries in which 93 per cent of adults and 99 per cent of children with HIV live.<ref>{{cite web |date=1 April 2014 |title=Medicines Patent Pool, ViiV Healthcare Sign Licence for the Most Recent HIV Medicine to Have Received Regulatory Approval |url=http://www.medicinespatentpool.org/medicines-patent-pool-viiv-healthcare-sign-licence-for-the-most-recent-hiv-medicine-to-have-received-regulatory-approval/ |url-status=live |archive-url=https://web.archive.org/web/20230602211728/https://medicinespatentpool.org/news-publications-post/medicines-patent-pool-viiv-healthcare-sign-licence-for-the-most-recent-hiv-medicine-to-have-received-regulatory-approval |archive-date=2 June 2023 |work=Medicines Patent Pool}}</ref> Also in 2013 GSK joined [[AllTrials]], a British campaign to ensure that all clinical trials are registered and the results reported. The company said it would make its past clinical-trial reports available and future ones within a year of the studies' end.<ref>[[Ben Goldacre]], ''[[Bad Pharma]]'', Fourth Estate, 2013 [2012], p. 387.</ref>

GSK has largely had an access strategy, providing medicines at a subsidized price to lower and middle income markets including Africa under the former CEO Andrew Witty. In 2017, its new CEO, Emma Walmsley,<ref>{{Cite web |last=Palmer |first=Eric |date=17 January 2018 |title=GSK cutting jobs in sub-Saharan Africa, will rely on distributors |url=https://www.fiercepharma.com/pharma/gsk-cutting-jobs-sub-saharan-africa-will-rely-distributors |url-status=live |archive-url=https://web.archive.org/web/20180118034343/https://www.fiercepharma.com/pharma/gsk-cutting-jobs-sub-saharan-africa-will-rely-distributors |archive-date=18 January 2018 |access-date=10 January 2023 |website=Fierce Pharma}}</ref> shifted away from this with GSK exiting all Sub-Saharan African markets and there being no plans to provide its newer expensive oncology and genetics pipeline to this population.<ref>{{Cite web |last=Mwangi |first=Kabui |date=15 October 2022 |title=GSK stops Nairobi production as high costs and low sales eat into revenue |url=https://www.theeastafrican.co.ke/tea/business/gsk-stops-nairobi-production-3986288 |url-status=live |archive-url=https://web.archive.org/web/20230609000152/https://www.theeastafrican.co.ke/tea/business/gsk-stops-nairobi-production-3986288 |archive-date=9 June 2023 |access-date=9 March 2023 |website=The East African |language=en}}</ref>